ARCHIVES

Immune System Booster Shown Safe For Prostate Cancer; Fewer Side Effects

This article is from The Cancer Letter archive.

Vol. 31 No. 8 | August 29, 2008

Download PDF Visit The Full Archive

Related Articles

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

October 31, 2014

ACS Research Budget Over $82 Million

July 17, 1987

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML

December 28, 2007

Rauscher Explains Reasons for Treatment Switches

May 9, 1975

In Brief: Columbia Still In Running As Comprehensive Center In ’78; Illinois Withdraws Application

June 24, 1977

NIH reiterates Position On Closed Meeting Of BSC Chairmen

September 23, 1994